Literature DB >> 11546903

Intrathecal baclofen for spastic hypertonia from stroke.

J M Meythaler1, S Guin-Renfroe, R C Brunner, M N Hadley.   

Abstract

BACKGROUND AND
PURPOSE: We sought to determine whether continuous intrathecal delivery of baclofen can effectively decrease spastic hypertonia due to stroke.
METHODS: Stroke patients with >6 months of intractable spasticity were screened via a randomized, double-blind, placebo-controlled crossover design of either intrathecal normal saline or 50 microgram baclofen. Those who dropped an average of 2 points in either their affected lower extremity side Ashworth or Penn spasm frequency scores were then offered computer-controlled pump implantation for continuous ITB and followed prospectively for up to 12 months.
RESULTS: In 21 stroke patients 6 hours after the active drug bolus, the average (+/-SD) lower extremity Ashworth score on the affected extremities decreased from 3.3+/-1.2 to 1.4+/-0.7 (P<0.0001), spasm score from 1.2+/-1.2 to 0.1+/-0.3 (P=0.0224), and reflex score from 2.1+/-1.2 to 0.1+/-0.5 (P<0.0001). The average upper extremity Ashworth score on the affected extremities decreased from 2.8+/-1.1 to 1.8+/-0.8 (P<0.0001), spasm score from 0.7+/-1.0 to 0.2+/-0.4 (P=0.1544), and reflex score from 2.1+/-0.9 to 1.2+/-0.9 (P=0.0004). All active drug scores were statistically different from placebo scores at 6 hours (P<0.05). With up to 12 months of continuous infusion of ITB in 17 implanted patients, the average lower extremity Ashworth score on the affected extremities decreased from 3.7+/-1.0 to 1.8+/-1.1 (P<0.0001), the spasm score dropped from 1.2+/-1.3 to 0.6+/-1.0 (P=0.4282), and the reflex score decreased from 2.4+/-1.3 to 1.0+/-1.3 (P<0.0001). The average upper extremity Ashworth score in the affected extremities decreased from 3.2+/-1.1 to 1.8+/-0.9 (P<0.0001), the spasm score dropped from 0.7+/-1.0 to 0.3+/-0.8 (P=0.8685), and the reflex score decreased from 2.4+/-0.8 to 1.5+/-1.2 (P=0.3337). The average continuous ITB dose required to attain these effects was 268 microgram/d.
CONCLUSIONS: Intrathecal infusion of baclofen is capable of maintaining a reduction in the spastic hypertonia resulting from stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546903     DOI: 10.1161/hs0901.095682

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  26 in total

Review 1.  New developments in stroke rehabilitation.

Authors:  Eugenio R Rocksmith; Michael J Reding
Journal:  Curr Atheroscler Rep       Date:  2002-07       Impact factor: 5.113

2.  [Intrathecal baclofen therapy in ambulatory patients with spastic hemiparesis following stroke. Short report of two cases].

Authors:  S Kästner
Journal:  Nervenarzt       Date:  2010-08       Impact factor: 1.214

Review 3.  Imaging evaluation of intrathecal baclofen pump-catheter systems.

Authors:  A C Miracle; M A Fox; R N Ayyangar; A Vyas; S K Mukherji; D J Quint
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

4.  Temporal facilitation of spastic stretch reflexes following human spinal cord injury.

Authors:  T George Hornby; Jennifer H Kahn; Ming Wu; Brian D Schmit
Journal:  J Physiol       Date:  2006-03-15       Impact factor: 5.182

Review 5.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Management of intrathecal baclofen therapy for severe acquired brain injury: consensus and recommendations for good clinical practice.

Authors:  Antonio De Tanti; Federico Scarponi; Michele Bertoni; Giulio Gasperini; Bernardo Lanzillo; Franco Molteni; Federico Posteraro; Dino Francesco Vitale; Mauro Zanpolini
Journal:  Neurol Sci       Date:  2017-05-06       Impact factor: 3.307

7.  A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.

Authors:  H W Heetla; J H Proost; B H Molmans; M J Staal; T van Laar
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

8.  Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.

Authors:  April Saval; Anthony E Chiodo
Journal:  J Spinal Cord Med       Date:  2010       Impact factor: 1.985

Review 9.  Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies.

Authors:  Stefan Hesse; Cordula Werner
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Comparison of transcutaneous electrical nerve stimulation (TENS) and functional electrical stimulation (FES) for spasticity in spinal cord injury - A pilot randomized cross-over trial.

Authors:  Anjali Sivaramakrishnan; John M Solomon; Natarajan Manikandan
Journal:  J Spinal Cord Med       Date:  2017-10-25       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.